The relationship between structural analysis of the hand and clinical characteristics in psoriatic arthritis

Alexander Pfeil (✉ alexander.pfeil@med.uni-jena.de)

Jena University Hospital – Friedrich Schiller University Jena

Marcus Heinz

Jena University Hospital – Friedrich Schiller University Jena

Tobias Hoffmann

Jena University Hospital – Friedrich Schiller University Jena

Tobias Weise

BioControl Jena

Diane M. Renz

Hannover Medical School

Marcus Franz

Jena University Hospital – Friedrich Schiller University Jena

Ansgar Malich

Suedharz-Hospital Nordhausen

Dominik Driesch

BioControl Jena

Peter Oelzner

Jena University Hospital – Friedrich Schiller University Jena

Gunter Wolf

Jena University Hospital – Friedrich Schiller University Jena

Joachim Böttcher

Jena University Hospital – Friedrich Schiller University Jena

Research Article

Keywords: Psoriatic arthritis, PsA, computer-based structural analysis, digital X-ray radiogrammetry, DXR, clinical characteristics, bone mineral density, BMD, computer-aided joint space analysis, CAJSA, finger joint space distance, JSD

Posted Date: February 28th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1226179/v2>

Abstract

Background:

Up to now, there is only limited information available on a possible relationship between clinical characteristics and the mineralization of metacarpal bones and finger joint space distance (JSD) in patients with psoriasis arthritis (PsA). Computerized digital imaging techniques like digital X-ray radiogrammetry (DXR) and computer-aided joint space analysis (CAJSA) have significantly improved the structural analysis of hand radiographs and facilitate the recognition of radiographic damage. The objective of this study was to evaluate clinical features which potentially influence periarticular mineralization of the metacarpal bones and finger JSD in PsA-patients.

Methods:

201 patients with PsA underwent computerized measurements of the metacarpal bone mineral density (BMD) with DXR and JSD of all finger joints by CAJSA. DXR-BMD and JSD were compared with clinical features such as age and sex, disease duration, C-reactive protein (CRP) as well as treatment with prednisone and disease-modifying antirheumatic drugs (DMARDs).

Results:

A longer disease duration and an elevated CRP value were associated with a significant reduction of DXR-BMD, whereas JSD-parameters were not affected by both parameters. DXR-BMD was significantly reduced in the prednisone group (-6.6%), but prednisone showed no impact on finger JSD. Patients under the treatment with bDMARDs presented significant lower DXR-BMD (-9.1%), JSD_{MCP} (-16.8%), and JSD_{PIP} (-12.4%) values.

Conclusion:

Metacarpal BMD was influenced by inflammatory activity, prednisone use, and DMARDs. In contrast, finger JSD showed only a change compared to baseline therapy. Therefore, metacarpal BMD as well as finger JSD represent radiographic destruction under different aspects.

Key Messages

- Both metacarpal BMD and finger JSD serve as markers of radiographic joint destruction in PsA-patients.
- Metacarpal BMD is significantly affected by inflammatory activity as well as the use of prednisone and DMARDs, with JSD showing a dependence on DMARDs.

- Consequently, both metacarpal BMD and finger JSD represent markers of radiographic damage, influenced by different clinical parameters.

Background

Psoriatic arthritis (PsA) is a multisystemic and chronic inflammatory musculoskeletal disease associated with cutaneous psoriasis, affecting most commonly the axial skeleton as well as peripheral joints of hands and feet (1, 2).

Conventional radiology has been the gold standard assessing the damage and radiographic progression in PsA (2, 3). As shown by Siannis et al., in the majority of patients radiological damage is detected before clinical damage is observed (4).

Computer-aided image analysis is increasingly utilized within radiology, connecting elements of artificial intelligence and computer vision with radiological image processing. Computer-based structural analysis of hand radiographs include digital X-ray radiogrammetry (DXR) and computer-aided joint space analysis (CAJSA). These diagnostic techniques allow the quantification of bone mineral density (BMD) and finger joint space distance (JSD) in rheumatoid arthritis (RA) and PsA (5-7). Therefore, DXR- and CAJSA-parameters serve as surrogate markers for radiological and structural damage as well as for radiological progression in RA (5, 8).

Some recent published studies revealed a demineralization of the metacarpal bones in PsA and BMD as an additional hallmark of radiographic damage in PsA (6, 9, 10). In addition, joint space narrowing of finger joints represents a characteristic radiologic feature of the PsA-associated joint destruction process (2).

So far, there is little information available regarding the relationship between clinical attributes and the mineralization of the metacarpal bones and finger JSD in patients with PsA. Therefore, the aim of our retrospective study was to evaluate clinical parameters which potentially influence periarticular mineralization of metacarpal bones as well as finger JSD in these patients.

Methods

The study enrolled 201 PsA-patients (79 men and 122 women) (Tab. 1). The mean age was 53.8 ± 13.6 years.

Clinical features

The following parameters were captured as clinical features: Disease duration, inflammatory activity measured by C-reactive protein (CRP) as well as therapy with prednisone, non-steroidal anti-inflammatory drugs (NSAIDs), coxibs and disease-modifying antirheumatic drugs (DMARDs). The mean disease duration was 6.8 ± 9.8 years and CRP was 10.1 ± 19.6 mg/l. 33 patients were administered prednisone

(mean dosage: 7.5 ± 8.2 mg). In addition, 116 subjects were treated with NSAIDs or coxibs, 58 patients received conventional synthetic DMARDs (csDMARDs), and 27 participants biological DMARDs (bDMARDs).

All subjects underwent radiographic examinations of the hands (anteroposterior view).

Computer-based structural analysis

Computer-based structural analysis of the hands included DXR for the quantification of metacarpal bone mineralization and CAJSA for the quantification of finger JSD.

Digital X-ray radiogrammetry

DXR (Pronosco X-Posure System™, Version 2.0; Sectra; Sweden) was applied to determine BMD (g/cm^2) (11). All plain radiographs were subsequently scanned (Scanner UMAX Power Look 1100, resolution 300 dots per inch) into the DXR system, turning them into digital images.

The system performs a continuous self-testing validation to maintain the quality of digital X-ray imaging, stopping the process when imaging becomes inferior (i.e. incorrect determination of bone contours and false identification of bone structures). The computer algorithms automatically defined regions of interest around the narrowest bone parts of the metacarpals II, III and IV and subsequently determined the outer and inner cortical edges of the cortical metacarpal bone parts and bone mineral density of the metacarpal bones (DXR-BMD) was verified.

Computer-aided joint space analysis:

CAJSA (Radiogrammetry Kit, Version 1.3.6; Sectra; Sweden) measured all JSD_{MCP} (metacarpophalangeal joints, thumb to small finger), JSD_{PIP} (proximal interphalangeal joints, index finger to small finger), and JSD_{DIP} (distal interphalangeal joints, index finger to small finger). The measurement procedure was performed as follows: Positioning of the region of interest to mark the particular joint to be measured. This is the only operator-dependent procedure in the entire measurement process. The CAJSA software is based on an automatic edge filtering within the region of interest identifying the specified joints. A 1.5 cm long edge across each bone was further determined and the distance between the two edges estimated as a function of the horizontal position. This was followed by calculation of the mean average and standard deviation of the distance over an extended interval of 0.8 cm by the CAJSA software. The distance between the bones was defined to be the edge interval for which the standard deviation is minimal. Additional, the Z-score as an age- and sex-independent parameter for the quantification of finger JSD was quantified (12).

Statistical analysis

Statistical computations were performed, using the programming language Python (version 3.6.9) and the additional packages NumPy (version 1.16.2), pandas (version 0.25.0), and Statsmodels (version

0.11.1). Data visualisation was carried out using the packages Matplotlib (version 3.3.0) and Seaborn (version 0.9.0).

The results of the DXR- and CAJSA-measurements were expressed as mean and standard deviation.

To adjust for age and sex-related changes in finger JSD that are disease-independent, Z-scores of all finger JSD were calculated according to Pfeil et al. 2009 (12) as followed:

$$\text{JSD-MCP}_{\text{patient}} - \text{JSD-MCP}_{\text{age and sex matched control}} / \text{standard deviation (SD)}_{\text{age and sex matched control}}$$

To adjust for age- and sex-related changes in BMD as well as disease-associated finger JSD, linear regressions models (statsmodels.formula.api.ols) were adjusted for DXR-BMD and all finger JSDs as well as their Z-scores as dependent variables (y_i), using age and sex as independent variables (Eq. X.1).

(X.1)

$$y_i = \beta_{0,i} + \beta_{1,i} * \text{age} + \beta_{2,i} * \text{sex}$$

The respective residuals of these models were used as dependent variables ($y_{\text{resid},i}$) in linear regression models for C-reactive protein (CPR), disease duration, prednisone and DMARDs treatment as independent variables (x_j). Furthermore, all Z-scores were adjusted for disease-associated age and sex-related effects accordingly (Eq. X.2).

(X.2)

$$y_{\text{resid},i} = \beta_{0,i} + \beta_{1,i} * x_j$$

To stabilize variance and compensate skewness, the continuous variables CRP and disease duration were log10 transformed prior to linear regression. Since disease duration included zeros, an off set of one year was added to disease duration before log10 transformation.

Anova Type II (statsmodels.stats.anova.anova_lm) was used for all linear regression models. P-values were reported to describe the influence of the respective independent variable on the respective dependent variable. P-values < 0.05 were considered as significant results.

Ethics approval

All examinations were performed in accordance with the rules and regulations of the local human research and Ethics Committee. The study protocol was approved by the Ethics Committee of the Friedrich-Schiller-University Jena, Germany (registration number 2018-1212). A consent was obtained from all subjects and/or their legal guardian(s). As a special note, the authors emphasize that all radiographs used for DXR- and CAJSA-calculations were performed as part of routine clinical care; no additional radiographs were obtained only for study purposes.

Results

Influence of age and sex on DXR-BMD, JSD, and Z-score (Fig. 1)

The linear regression revealed a significant negative influence of age (regression coefficient $\beta = -2.26e-03$; $P < 0.001$) and sex ($\beta = -2.72e-02$; $P < 0.01$) on DXR-BMD. Regarding the interaction of age and JSD, a significant β of $-7.37e-04$ (MCP), $-4.43e-04$ (PIP), and $-7.32e-04$ (DIP) was shown. Linear regression analysis showed no significant association between JSD and sex. Age had no significant influence on the Z-score, whereas the linear regression analysis showed for sex a significant β with $7.72e-01$ (Z-score_{MCP}) and $3.15e-01$ (Z-score_{PIP}) on the Z-score.

Influence of DMARDs- and prednisone treatment, disease duration, and CRP on DXR-BMD, JSD, and Z-score

DXR-BMD (Tab. 2-5, Fig. 2):

Regarding disease duration, there was a significant reduction of the DXR-BMD (difference -0.011 g/cm², -6.6%) between a disease duration less than two years (DXR-BMD: 0.545 ± 0.076 g/cm²) and more than ten years (DXR-BMD: 0.509 ± 0.070 g/cm²) ($\beta = -2.25e-02$; $P < 0.05$).

Concerning CRP levels, a significant change was evaluated for DXR-BMD (difference: -0.04 g/cm² and -0.7% ; $\beta = -2.18e-02$; $P < 0.05$).

An equivalent result was observed for treatment with prednisone on DXR-BMD ($\beta = -2.83e-02$ [$P < 0.05$], DXR-BMD_{mean prednisone_{group-treated}}: 0.509 ± 0.068 g/cm² versus DXR-BMD_{mean prednisone_{group-untreated}}: 0.545 ± 0.074 g/cm², difference -0.037 g/cm² versus -6.6%). Linear regression analysis evaluated a $\beta = -1.85e-02$ for DMARDs. Patients treated with bDMARDs presented a significant lower DXR-BMD (difference -0.050 g/cm² and -9.1%), compared to patients treated with NSAIDs/coxibs.

JSD (Tab. 2-5, Fig. 3):

Disease duration (JSD_{MCP}: difference -0.019 cm and -11.5% , JSD_{PIP} difference -0.002 cm and -1.8% , and JSD_{DIP} difference -0.007 cm and -8.4% , $P = n. s.$) and CRP (JSD_{MCP}: difference 0 cm and 0% , $P = n. s.$; JSD_{PIP} difference -0.001 cm and -0.9% , $P = n. s.$ and JSD_{DIP} difference 0.002 cm and 2.2% , $P = n. s.$) showed no significant association to all JSD-parameters in the regression analysis.

This also applies to prednisone, showing no significant impact on finger JSD (JSD_{MCP}: difference -0.004 cm and -2.5% ; $\beta = -1.40e-03$; $P = n. s.$; JSD_{PIP}: difference -0.004 cm and -3.6% ; $\beta = -2.51e-03$; $P = n. s.$ as well as JSD_{DIP}: difference -0.002 cm and -2.2% ; $\beta = 1.052e-03$; $P = n. s.$).

Furthermore, linear regression analysis revealed an influence of DMARDs on JSD_{MCP} (difference -0.028 cm and -16.8% ; $\beta = -1.19e-02$; $P < 0.001$) and JSD_{PIP} (difference -0.020 cm and -12.4% ; $\beta = -5.25e-03$; P

< 0.05). DMARDs (difference: - 0.015 cm and - 15.6%; $\beta = 4.3781e-03$; $P = n. s.$) revealed no significant linear regression analysis to JSD_{DIP} .

Z-score (Tab. 2-5, Fig. 4):

No association was found between the Z-score and the treatment with disease duration ($Z\text{-score}_{MCP}$: difference - 0.43, $\beta = -4.45e-01$, $P = < 0.05$; $Z\text{-score}_{PIP}$: difference - 0.01, $\beta = -4.76e-02$, $p = n. s.$, and $Z\text{-score}_{DIP}$: difference - 0.14, $\beta = -1.48e-01$, $P = n. s.$), CRP ($Z\text{-score}_{MCP}$: difference - 0.14, $\beta = -1.08e-01$, $P = n. s.$; $Z\text{-score}_{PIP}$: difference - 0.07, $\beta = -1.63e-01$, $P = n. s.$, and $Z\text{-score}_{DIP}$: difference - 0.22, $\beta = -5.75e-02$, $P = n. s.$) and prednisone ($Z\text{-score}_{MCP}$: difference - 0.06, $\beta = -9.40e-02$, $p = n. s.$; $Z\text{-score}_{PIP}$: difference - 0.01, $\beta = -1.69e-01$, $P = n. s.$ and $Z\text{-score}_{DIP}$: difference - 0.09, $\beta = -7.83e-02$, $P = n. s.$).

In accordance with JSD, the Z-score of MCP- ($\beta = -3.96e-01$; $p < 0.001$) and PIP-joints ($\beta = -2.45e-01$; $p < 0.05$) was influenced by bDMARDs with a reduction of the $Z\text{-score}_{MCP}$ (-0.83) and $Z\text{-score}_{PIP}$ (-0.52), whereas the $Z\text{-score}_{DIP}$ was not significantly reduced.

Discussion

In contrast to the significant improvement in the understanding of the pathogenesis and treatment of PsA in the last ten years, there is only little known regarding the impact of clinical features on structural and radiological damage. To close this gap, the aim of our retrospective study was to quantify clinical parameters which influence periarticular mineralization of the metacarpal bones and finger JSD in PsA-patients.

In our study, a decrease in DXR-BMD was found for both disease duration and elevated CRP. In addition, prednisone use was associated with a decreased DXR-BMD. However, these parameters did not have an impact on JSD and Z-score. Furthermore, we demonstrated a decrease in DXR-BMD and JSD_{MCP} as well as JSD_{PIP} under therapy with bDMARDs.

Computer-aided techniques including DXR and CAJSA serve as innovative tools in the quantification of radiological damage (5, 6, 13). The computer-based structural analysis of hand radiographs offers significant advantages in the quantification of radiographic damage in inflammatory arthritis (e. g. RA and PsA) in comparison with conventional scoring of hand radiographs (6, 13-15). Mainly, the computer-based measurement of DXR-BMD (coefficient of variation: 0.13% - 1.50%) and CAJSA-JSD (coefficient of variation: 0.38 – 0.66%) provide a high reproducibility, compared to standard scoring methods for the detection of radiographic damage (e. g. reproducibility of the van der Heijde modification of the Sharp Score: 1.8 – 3.8%) (16-18). Therefore, detailed changes of bone structure and JSD are noticeable, especially with regard to the detection of treatment effects, and represent markers for structural damage (13-15).

The present study evaluated the influence of clinical features such as disease duration, inflammatory activity, prednisone use, and other different treatment strategies on structural parameters of the hands as measured by DXR-BMD and finger JSD in PsA-patients.

In our study, PsA-patients with a disease duration of more than ten years showed a significantly reduced DXR-BMD (- 6.6%), JSD_{MCP} (- 11.5%), and Z-Score_{MCP} (- 0.43). This is in accordance with previous data, which revealed an increase of erosive bone changes in PsA, depending on disease duration as measured with high-resolution peripheral quantitative computed-tomography (HR-pQCT) (24). In this context, the results of our study revealed a significant influence of age on DXR-BMD and finger JSD in PsA patients which has also been shown in healthy subjects (19-21). Simon et al. reported a lower volumetric articular BMD of the MCP-joints, measured by HR-pQCT in PsA-patients, compared with healthy subjects (22). In addition, patients with RA showed a significantly reduced DXR-BMD (- 20.7%) and JSD of MCP-joints (- 18.9%) versus a healthy control group (12, 23). Sex had an additional impact on DXR-BMD, whereas JSD was not influenced. As demonstrated before, the DXR-BMD in healthy women is significantly lower (-12.8%) versus healthy men (19).

Inflammatory activity is strongly associated with radiographic damage in PsA (25). Regarding inflammatory activity as measured by CRP levels, PsA-patients with increased CRP values showed a reduced DXR-BMD (- 0.7%). The linear regression models yielded a significant impact of CRP on DXR-BMD. Furthermore, Wu et al. reported a significant bone loss of the second and third metacarpal bone head, quantified by HR-pQCT in association with elevated CRP values in PsA-patients (26). These results highlight the strong interaction of inflammatory activity and demineralization of metacarpal bones in inflammatory arthritis which was also published for RA (27, 28). Additionally, CRP served as an independent predictor of radiographic progression in PsA (29). At the time of initial diagnosis, elevated CRP levels were associated with new erosions as a marker for radiographic progression (30).

In our study, JSD-parameters assessed with CAJSA were not influenced by CRP. In accordance with these results, a longitudinal study showed that an elevated baseline CRP was not related to joint space narrowing, as quantified by van der Heijde-modified total Sharp score for PsA (33).

We demonstrated, that treatment with prednisone was associated with a significant reduction of DXR-BMD (- 6.6%). A negative correlation between the change of DXR-BMD over 24 months and the use of corticosteroids ($r = - 0.27$; $P < 0.005$) was also observed by Hoff et al. (10). These results indicate that corticosteroids can lead to a demineralization of metacarpal bones. The JSD-parameters in our study revealed no significant changes in association with prednisone treatment. Bond et al. showed an increase of radiological damage, assessed with the Steinbrocker staging system under corticosteroids (31), where the Steinbrocker method represented a composite score including the quantification of periarticular demineralisations, erosions, joint space narrowing and ankyloses.

Recently published studies showed periarticular demineralization (6, 9, 10, 24, 25) and severity-dependent bone loss in patients with PsA (6). Additionally, finger joint space narrowing represented a common

radiographic hallmark for structural damage in PsA (26, 27). In summary, both parameters reflected PsA-associated radiographic damage (6, 27). In the present study, treatment with bDMARDs resulted in a significant lower DXR-BMD (- 6.6%), JSD_{MCP} (- 11.5%), and Z-score_{MCP} (- 0.83), compared to csDMARDs and NSAIDs. Concerning DXR-BMD and CAJSA-JSD as radiographic markers of damage and disease severity (5, 8), bDMARDs-treated patients in our study showed more structural damage, which is explainable with the advanced course of the disease. According to the updated recommendations of the European League Against Rheumatism (EULAR) for the treatment of PsA, this led to the treatment with bDMARDs (32).

Additionally, radiographic damage in PsA is a potential risk factor for disease progression. In our study, DXR-BMD was influenced by inflammatory activity, prednisone use, and treatment with DMARDs. In contrast, the reduction of JSD measured by CAJSA-JSD was only significantly affected by DMARDs. Consequently, JSD serves as parameter for monitoring treatment with DMARDs. Therefore, both DXR-BMD and JSD represent radiographic damage under different aspects.

As a result, patients with an accentuated radiographic damage should be treated earlier with bDMARDs to avoid radiographic structural damage. In this case, the use of csDMARDs should be critically questioned, whereas bDMARDs revealed also higher response rates and reduced radiographic progression in PsA (33). Radiographic damage and progression correlated with the Health Assessment Questionnaire (HAQ) as outcome marker for disability (34).

Our study is potentially limited by the cross-sectional design. Further investigations are needed to verify these results in a longitudinal study design. However, the present study offered the first insights of the influence of clinical features on DXR-BMD and JSD as surrogate markers of radiographic damage in PsA patients.

Conclusion

In conclusion, metacarpal BMD measured by DXR and finger JSD quantified by CAJSA are established markers in the quantification of radiographic damage in PsA-patients. Metacarpal BMD was more influenced by clinical factors like disease duration, inflammatory activity, prednisone, and DMARDs compared to finger JSD which was significantly reduced by DMARDs. In this context, DXR-BMD and JSD represent radiographic damage under different aspects.

Abbreviations

bDMARDs	B iological d isease- m odifying a nti- r heumatic d rugs
CAJSA	C omputer- a ided j oint s pace a nalysis
CRP	C -reactive p rotein

csDMARDs	Conventional s ynthetic d isease- m odifying a ntirheumatic d rugs
DIP	Distal inter p halangeal joint
DXR	Digital X -ray radiogrammetry
DXR-BMD	Bone m ineral d ensity (g/cm ²) estimated by DXR
HR-pQCT	High- r esolution p eripheral q uantitative c omputed- t omography
JSD	Joint s pace d istance
MCP	Meta c arpophalangeal joint
NSAIDs	Non- s teroidal a nti- i nflammatory d rugs
n.s.	Not s ignificant
PIP	Proximal inter p halangeal joint
PsA	Psoriatic a rthritis
SD	Standard d eviation

Declarations

Acknowledgements

The authors would like to thank Ms. Monika Arens (managing director, Arewus GmbH) and Mr. Jacob Algulin (managing director, Sectra, Sweden) for the use of the digital X-ray radiogrammetry and the computer-aided joint space analysis. Many thanks to Prof. Dr. Desiree van der Heijde (Leiden University Medical Center, Leiden, The Netherlands) and Prof. Dr. Robert Landewé (University Hospital Maastricht, Maastricht, The Netherlands) regarding their comments to our study. Also many thanks to Ms. Dr. rer. nat. Kirsten Hessel (Novartis Pharma GmbH, Nürnberg, Germany) for the support in performing the investigator-initiated study in Jena, Germany and for the helpful critical discussion of the data.

Authors contributions

A.P. and J.B. designed the study, analysed the radiographs, performed the statistical analysis, wrote the manuscript and revised the manuscript. M.H. performed the DXR- and CAJSA-analysis as well as the study design. T.W. and D.D. performed the statistical analysis. D.R. and M.F. interpreted the data and helped to draft the manuscript. P.O. edited the manuscript. G.W. interpreted the data and edited the manuscript. A.M. participated on the study design, and wrote the manuscript. All authors reviewed the manuscript.

Funding

This study is a part of the Investigator Initiated study “The quantification of radiographic destruction and progression of psoriatic arthritis using computer based structure analysis” which is supported by Novartis Pharma GmbH, Roonstraße 25, 990429 Nürnberg, Germany.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval

All examinations were performed in accordance with the rules and regulations of the local human research and Ethics Committee. The study protocol was approved by the Ethics Committee of the Friedrich-Schiller-University Jena, Germany (registration number 2018-1212). A consent was obtained from all subjects and/or their legal guardian(s). As a special note, the authors emphasize that all radiographs used for DXR- and CAJSA-calculations were performed as part of routine clinical care; no additional radiographs were obtained only for study purposes.

Consent for publication

Not applicable.

Competing interest

Alexander Pfeil, Marcus Heinz, Tobias Hoffmann, Tobias Weise, Diane M. Renz, Marcus Franz, Ansgar Malich, Dominik Driesch, Peter Oelzner, Gunter Wolf, Joachim Böttcher declare that they have no competing interests.

Author details

¹Department of Internal Medicine III, Jena University Hospital – Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany

² BioControl Jena, Hans-Knöll-Straße 6, 07745 Jena, Germany

³ Institute of Diagnostic and Interventional Radiology, Department of Pediatric Radiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

⁴ Department of Internal Medicine I, Jena University Hospital – Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany

References

1. Ocampo DV, Gladman D. Psoriatic arthritis. *F1000Res*. 2019;8.
2. Wassenberg S. Radiographic scoring methods in psoriatic arthritis. *Clin Exp Rheumatol*. 2015;33(5 Suppl 93):S55-9.
3. van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. *Ann Rheum Dis*. 2005;64 Suppl 2:ii61-4.
4. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. *Ann Rheum Dis*. 2006;65(4):478-81.
5. Pfeil A, Oelzner P, Bornholdt K, Hansch A, Lehmann G, Renz DM, et al. Joint damage in rheumatoid arthritis: assessment of a new scoring method. *Arthritis Res Ther*. 2013;15(1):R27.
6. Pfeil A, Krojniak L, Renz DM, Reinhardt L, Franz M, Oelzner P, et al. Psoriatic arthritis is associated with bone loss of the metacarpals. *Arthritis Res Ther*. 2016;18(1):248.
7. Pfeil A, Oelzner P, Renz DM, Lehmann G, Wolf G, Boettcher J. Visualisation of structural damage as a surrogate marker of radiographic progression in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2014;73(4):e24.
8. Pfeil A, Haugeberg G, Hansch A, Renz DM, Lehmann G, Malich A, et al. Value of digital X-ray radiogrammetry in the assessment of inflammatory bone loss in rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2011;63(5):666-74.
9. Kocijan R, Englbrecht M, Haschka J, Simon D, Kleyer A, Finzel S, et al. Quantitative and Qualitative Changes of Bone in Psoriasis and Psoriatic Arthritis Patients. *J Bone Miner Res*. 2015;30(10):1775-83.
10. Hoff M, Kavanaugh A, Haugeberg G. Hand bone loss in patients with psoriatic arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. *J Rheumatol*. 2013;40(8):1344-8.
11. Rosholm A, Hyldstrup L, Backsgaard L, Grunkin M, Thodberg HH. Estimation of bone mineral density by digital X-ray radiogrammetry: theoretical background and clinical testing. *Osteoporos Int*. 2001;12(11):961-9.
12. Pfeil A, Schafer ML, Lehmann G, Seidl BE, Eidner T, Malich A, et al. Implementation of Z-scores as an age- and sex-independent parameter for estimating joint space widths in rheumatoid arthritis. *J Rheumatol*. 2009;36(4):717-23.
13. Pfeil A, Oelzner P, Renz DM, Hansch A, Wolf G, Bottcher J. Is there a role for Digital X-ray Radiogrammetry as surrogate marker for radiological progression and imaging of structural integrity in rheumatoid arthritis? *BMC Musculoskelet Disord*. 2015;16:155.
14. Pfeil A, Nussbaum A, Renz DM, Jung C, Oelzner P, Malich A, et al. Inhibition of periarticular bone loss is associated with clinical remission and ACR70-Response in rheumatoid arthritis. *Rheumatol Int*.

2019;39(4):637-45.

15. Pfeil A, Nussbaum A, Renz DM, Hoffmann T, Malich A, Franz M, et al. Radiographic remission in rheumatoid arthritis quantified by computer-aided joint space analysis (CASJA): a post hoc analysis of the RAPID 1 trial. *Arthritis Res Ther*. 2020;22(1):229.
16. Pfeil A, Hansch A, Sommerfeld J, Frober R, Renz DM, Lehmann G, et al. Reproducibility and influence of hand rotation on computer-aided joint space analysis. *Joint Bone Spine*. 2012;79(4):384-8.
17. Bottcher J, Pfeil A, Rosholm A, Malich A, Petrovitch A, Heinrich B, et al. Influence of image-capturing parameters on digital X-ray radiogrammetry. *J Clin Densitom*. 2005;8(1):87-94.
18. Rau R, Wassenberg S. [Imaging techniques in rheumatology: scoring methods in rheumatoid arthritis]. *Z Rheumatol*. 2003;62(6):555-65.
19. Bottcher J, Pfeil A, Schafer ML, Petrovitch A, Seidl BE, Mentzel HJ, et al. Normative data for digital X-ray radiogrammetry from a female and male German cohort. *J Clin Densitom*. 2006;9(3):341-50.
20. Pfeil A, Bottcher J, Schafer ML, Seidl BE, Schmidt M, Petrovitch A, et al. Normative reference values of joint space width estimated by computer-aided joint space analysis (CAJSA): the distal interphalangeal joint. *J Digit Imaging*. 2008;21 Suppl 1:104-12.
21. Pfeil A, Bottcher J, Seidl BE, Heyne JP, Petrovitch A, Eidner T, et al. Computer-aided joint space analysis of the metacarpal-phalangeal and proximal-interphalangeal finger joint: normative age-related and gender-specific data. *Skeletal Radiol*. 2007;36(9):853-64.
22. Simon D, Kleyer A, Englbrecht M, Stemmler F, Simon C, Berlin A, et al. A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin. *Bone*. 2018;116:87-93.
23. Pfeil A, Haugeberg G, Renz DM, Reinhardt L, Jung C, Franz M, et al. Digital X-ray radiogrammetry and its sensitivity and specificity for the identification of rheumatoid arthritis-related cortical hand bone loss. *J Bone Miner Metab*. 2017;35(2):192-8.
24. Simon D, Kleyer A, Faustini F, Englbrecht M, Haschka J, Berlin A, et al. Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration. *Arthritis Res Ther*. 2018;20(1):203.
25. Aletaha D, Alasti F, Smolen JS. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. *Ann Rheum Dis*. 2017;76(2):418-21.
26. Wu D, Griffith JF, Lam SHM, Wong P, Yue J, Shi L, et al. Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. *Osteoporos Int*. 2020;31(5):941-50.
27. Pye SR, Adams JE, Ward KA, Bunn DK, Symmons DP, O'Neill TW. Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss. *Rheumatology (Oxford)*. 2010;49(10):1943-8.
28. Bøyesen P, Hoff M, Odegård S, Haugeberg G, Syversen SW, Gaarder PI, et al. Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study. *Arthritis Res Ther*. 2009;11(4):R103.

29. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. *Arthritis Res Ther.* 2010;12(3):R113.
30. Haroon M, Gallagher P, Ahmad M, FitzGerald O. Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis. *Clin Rheumatol.* 2020;39(10):2951-61.
31. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. *Ann Rheum Dis.* 2007;66(3):370-6.
32. Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis.* 2020;79(6):778-86.
33. Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. *Arthritis Rheumatol.* 2019;71(7):1112-24.
34. Feced Olmos CM, Alvarez-Calderon O, Hervás Marín D, Ivorra Cortés J, Pujol Marco C, Román Ivorra JA. Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients. *Clin Biomech (Bristol, Avon).* 2019;68:169-74.
35. Pfeil A, Renz DM, Hansch A, Kainberger F, Lehmann G, Malich A, et al. The usefulness of computer-aided joint space analysis in the assessment of rheumatoid arthritis. *Joint Bone Spine.* 2013;80(4):380-5.

Tables

Table 1: Baseline characteristics (CRP = C-reactive protein, NSAIDs = Non-steroidal anti-inflammatory drugs, csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; bDMARDs = biological disease-modifying antirheumatic drugs).

Patients	N = 201
Women	N = 124
Men	N = 84
Age (in years) mean $\pm$ SD	53.8 $\pm$ 13.6
Disease duration (in years), mean $\pm$ SD	6.8 $\pm$ 9.8 years
CRP (in mg/l) mean $\pm$ SD	10.1 $\pm$ 19.6 mg/l
Prednisone	N = 33 mean dosage: 7.5 $\pm$ 8.2 mg
NSAIDs/coxibs	N = 116
csDMARDs	N = 58
bDMARDs	N = 27

Table 2: Quantification of periarticular demineralization and finger JSD depending on disease duration (DXR-BMD = Bone mineral density (g/cm²), estimated by digital X-ray radiogrammetry, JSD = Joint space distance, MCP = Metacarpophalangeal joint, PIP = proximal interphalangeal joint, DIP = Distal interphalangeal joint).

	Disease duration < 2 years mean $\pm$ SD <i>N</i> = 98	Disease duration 3 to 9 years mean $\pm$ SD <i>N</i> = 52	Disease duration > 10 years mean $\pm$ SD <i>N</i> = 51	Difference between disease duration < 2 years and > 10 years
DXR-BMD in g/cm ²	0.545 $\pm$ 0.076	0.556 $\pm$ 0.070	0.509 $\pm$ 0.070	- 0.036 g/cm ² (- 6.6 %)
JSD _{MCP} in cm	0.165 $\pm$ 0.024	0.164 $\pm$ 0.030	0.146 $\pm$ 0.040	- 0.019 cm (- 11.5 %)
JSD _{PIP} in cm	0.110 $\pm$ 0.022	0.111 $\pm$ 0.023	0.108 $\pm$ 0.022	- 0.002 cm (- 1.8 %)
JSD _{DIP} in cm	0.095 $\pm$ 0.034	0.092 $\pm$ 0.023	0.087 $\pm$ 0.028	- 0.007 cm (- 8.4 %)
Z-score _{MCP}	- 0.28 $\pm$ 0.88	- 0.17 $\pm$ 0.98	- 0.71 $\pm$ 1.41	- 0.43
Z-score _{PIP}	- 0.11 $\pm$ 1.03	- 0.02 $\pm$ 1.05	- 0.12 $\pm$ 0.95	- 0.01
Z-score _{DIP}	- 0.40 $\pm$ 1.27	- 0.37 $\pm$ 1.06	- 0.54 $\pm$ 1.36	- 0.14

Table 3: Influence of CRP on periarticular mineralization and finger JSD (DXR-BMD = Bone mineral density (g/cm²), estimated by digital X-ray radiogrammetry, JSD = Joint space distance, MCP = Metacarpophalangeal joint, PIP = Proximal-interphalangeal joint, DIP = Distal-interphalangeal joint).

	CRP < 7,5 mg/l mean ± SD (N = 142)	CRP > 7,5 mg/l mean ± SD (N = 59)	Difference
DXR-BMD in g/cm ²	0.540 ± 0.076	0.536 ± 0.073	- 0.004 g/cm ² (- 0.7 %)
JSD _{MCP} in cm	0.16 0± 0.029	0.160 ± 0.035	0 cm (0 %)
JSD _{PIP} in cm	0.110 ± 0.021	0.109 ± 0.024	- 0.001 cm (- 0.9 %)
JSD _{DIP} in cm	0.091 ± 0.030	0.093 ± 0.030	+ 0.002 cm (2.2 %)
Z-score _{MCP}	- 0.40 ± 1.00	- 0.26 ± 1.23	- 0.14
Z-score _{PIP}	- 0.11 ± 0.98	- 0.04 ± 1.09	- 0.07
Z-score _{DIP}	- 0.49 ± 1.13	- 0.27 ± 1.46	- 0.22

Table 4: Effect of corticosteroids on periarticular bone loss and JSD (DXR-BMD = Bone mineral density (g/cm²), estimated by digital X-ray radiogrammetry, JSD = Joint space distance, MCP = Metacarpophalangeal joint, PIP = Proximal interphalangeal joint, DIP = Distal interphalangeal joint).

	No prednisone mean ± SD (N = 168)	Prednisone mean ± SD (N = 33)	Difference
DXR-BMD in g/cm ²	0.545 ± 0.075	0.509 ± 0.067	- 0.037 g/cm ² (- 6.6 %)
JSD _{MCP} in cm	0.161 ± 0.029	0.157 ± 0.044	- 0.004 cm (- 2.5 %)
JSD _{PIP} in cm	0.110 ± 0.021	0.106 ± 0.029	- 0.004 cm (- 3.6 %)
JSD _{DIP} in cm	0.092 ± 0.029	0.090 ± 0.033	- 0.002 cm (- 2.2 %)
Z-score _{MCP}	- 0.37 ± 1.01	- 0.31 ± 1.35	- 0.06
Z-score _{PIP}	- 0.09 ± 0.98	- 0.08 ± 1.17	- 0.01
Z-score _{DIP}	- 0.44 ± 1.13	- 0.35 ± 1.63	- 0.09

Table 5: Changes of the DXR-BMD and finger JSD as measured by the Z-score dependent on the treatment strategy (DXR-BMD = Bone mineral density (g/cm²), estimated by digital X-ray radiogrammetry, JSD = Joint space distance, MCP = Metacarpophalangeal joint, PIP = Proximal-interphalangeal joint, DIP = Distal-interphalangeal joint).

	NSAIDs or coxibs	csDMARDs	bDMARDs	Difference between NSAIDs/coxibs vs. bDMARDs
	Mean ± SD (N = 116)	Mean ± SD (N = 58)	Mean ± SD (N = 27)	
DXR-BMD in g/cm ²	0.550 ± 0.075	0.534 ± 0.073	0.500 ± 0.065	- 0.050 g/cm ²
JSD _{MCP} in cm	0.167 ± 0.026	0.155 ± 0.032	0.139 ± 0.039	- 0.028 cm (-16.8 %)
JSD _{PIP} in cm	0.113 ± 0.023	0.10 8 ± 0.019	0.099 ± 0.022	- 0.020 cm (-12.4 %)
JSD _{DIP} in cm	0.096 ± 0.032	0.089 ± 0.025	0.081 ± 0.027	- 0.015 cm (-15.6 %)
Z-score _{MCP}	- 0.22 ± 0.86	- 0.32 ± 1.16	- 1.05 ± 1.44	- 0.83
Z-score _{PIP}	- 0.10 ± 1.06	- 0.06 ± 0.81	- 0.6 2 ± 1.09	- 0.52
Z-score _{DIP}	- 0.35 ± 1.21	- 0.37 ± 1.21	- 0.87 ± 1.34	- 0.52

Figures

Figure 1

Adjustment of bone mineral density (BMD), measured by digital X-ray radiogrammetry (DXR), finger JSD, and Z-score (metacarpophalangeal joint [MCP], proximal interphalangeal joint [PIP] [1], distal interphalangeal joint [DIP]) as quantified by computer-aided joint space analysis (CAJSA) regarding age and sex (**A**: $P = 5.5\text{e-}03$ [$P < 0.05$], $P = 6.3\text{e-}10^*$ [$P < 0.001$]; **B**: $P = 1.6\text{e-}01$ [$P = \text{n. s.}$], $P = 2.5\text{e-}06^*$ [$P < 0.001$]; **C**: $P = 6.0\text{e-}02$ [$P = \text{n. s.}$], $7.4\text{e-}05^*$ [$P < 0.001$]; **D**: $P = 8.4\text{e-}02$ [$P = \text{n. s.}$], $3.8\text{e-}08^*$ [$P < 0.001$]; **E**: $3.7\text{e-}07^*$ [$P < 0.001$], $P = 2.7\text{e-}02$ [$P < 0.05$], $P = 1.9\text{e-}01$ [$P = \text{n. s.}$]).

Figure 2

Linear regression model for DMARDs, prednisone, disease duration, and CRP as independent variables of bone mineral density (DXR-BMD) after the correction of age and sex (**A**. $P = 4.4e-03$ [$P < 0.05$]; **B**. $P = 2.6e-02$ [$P < 0.05$]; **C**. $P = 2.0e-02$ [$P < 0.05$]; **D**. $P = 4.2e-02$ [$P < 0.05$]).

Figure 3

Linear regression model for DMARDs, prednisone, disease duration, and CRP as independent variables on JSD (metacarpophalangeal joint [MCP], proximal interphalangeal joint [PIP], distal interphalangeal joint [DIP]) after the correction of age and sex (**A**: $P = 2.2 \times 10^{-5}$ [$P < 0.001$]; **B**: $P = 8.0 \times 10^{-1}$ [$P = \text{n. s.}$]; **C**: $P = 2.0 \times 10^{-3}$ [$P < 0.05$]; **D**: $P = 7.7 \times 10^{-1}$ [$P = \text{n. s.}$]; **E**: $P = 1.0 \times 10^{-2}$ [$P < 0.05$]; **F**: $P = 5.3 \times 10^{-1}$ [$P = \text{n. s.}$]; **G**: $P = 6.8 \times 10^{-1}$ [$P = \text{n. s.}$]; **H**: $P = 4.6 \times 10^{-1}$ [$P = \text{n. s.}$]; **I**: $P = 7.0 \times 10^{-2}$ [$P = \text{n. s.}$]; **J**: $P = 8.2 \times 10^{-1}$ [$P = \text{n. s.}$]; **K**: $P = 2.4 \times 10^{-1}$ [$P = \text{n. s.}$]; **L**: $P = 3.0 \times 10^{-1}$ [$P = \text{n. s.}$]).

Figure 4

Linear regression model for DMARDs, prednisone, disease duration, and CRP as independent variables on the Z-score (metacarpophalangeal joint [MCP], proximal interphalangeal joint [PIP], distal interphalangeal joint [DIP]) after the correction of age and sex (**A**: $P = 4.9e-05$ [$P < 0.001$]; **B**: $P = 6.3e-01$ [$P = \text{n. s.}$]; **C**: $P = 2.2e-03$ [$P < 0.05$]; **D**: $P = 5.1e-01$ [$P = \text{n. s.}$]; **E**: $P = 1.0e-02$ [$P < 0.05$]; **F**: $P = 3.6e-01$ [$P = \text{n. s.}$]; **G**: $P = 7.4e-01$ [$P = \text{n. s.}$]; **I**: $P = 3.0e-01$ [$P = \text{n. s.}$]; **J**: $P = 6.1e-02$ [$P = \text{n. s.}$]; **K**: $P = 7.2e-01$ [$P = \text{n. s.}$]; **L**: $P = 3.7e-01$ [$P = \text{n. s.}$]; **M**: $P = 7.5e-01$ [$P = \text{n. s.}$]).